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Further clinical and molecular delineation of the 9q subtelomeric
deletion syndrome supports a major contribution of EHMT1
haploinsufficiency to the core phenotype
Abstract
BACKGROUND: The 9q subtelomeric deletion syndrome (9qSTDS) is clinically characterised by
moderate to severe mental retardation, childhood hypotonia and facial dysmorphisms. In addition,
congenital heart defects, urogenital defects, epilepsy and behavioural problems are frequently observed.
The syndrome can be either caused by a submicroscopic 9q34.3 deletion or by intragenic EHMT1
mutations leading to haploinsufficiency of the EHMT1 gene. So far it has not been established if and to
what extent other genes in the 9q34.3 region contribute to the phenotype observed in deletion cases.
This study reports the largest cohort of 9qSTDS cases so far. METHODS AND RESULTS: By a
multiplex ligation dependent probe amplification (MLPA) approach, the authors identified and
characterised 16 novel submicroscopic 9q deletions. Direct sequence analysis of the EHMT1 gene in 24
patients exhibiting the 9qSTD phenotype without such deletion identified six patients with an intragenic
EHMT1 mutation. Five of these mutations predict a premature termination codon whereas one mutation
gives rise to an amino acid substitution in a conserved domain of the protein. CONCLUSIONS: The
data do not provide any evidence for phenotype-genotype correlations between size of the deletions or
type of mutations and severity of clinical features. Therefore, the authors confirm the EHMT1 gene to
be the major determinant of the 9qSTDS phenotype. Interestingly, five of six patients who had reached
adulthood had developed severe psychiatric pathology, which may indicate that EHMT1
haploinsufficiency is associated with neurodegeneration in addition to neurodevelopmental defect.
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Abstract 
The 9q Subtelomeric Deletion Syndrome (9qSTDS) is clinically characterized by 
moderate to severe mental retardation, childhood hypotonia and facial dysmorphisms. In 
addition, congenital heart defects, urogenital defects, epilepsy and behavioral problems 
are frequently observed. The syndrome can be either caused by a submicroscopic 9q34.3 
deletion or by intragenic EHMT1 mutations leading to haploinsufficiency of the EHMT1 
gene. So far it has not been established if and to what extent other genes in the 9q34.3 
region contribute to the phenotype observed in deletion cases. 
Here we report the largest cohort of 9qSTDS cases so far. By a Multiplex Ligation 
dependent Probe Amplification approach, we identified and characterized 16 novel 
submicroscopic 9q deletions. Direct sequence analysis of the EHMT1 gene in 24 patients 
exhibiting the 9qSTD phenotype without such deletion, identified 6 patients with an 
intragenic EHMT1 mutation. Five of these mutations predict a premature termination 
codon whereas one mutation gives rise to an amino acid substitution in a conserved 
domain of the protein. 
Our data do not provide any evidence for phenotype-genotype correlations between size 
of the deletions or type of mutations and severity of clinical features. Therefore, we 
confirm the EHMT1 gene to be the major determinant of the 9qSTDS phenotype. 
Interestingly, five of six patients who had reached adulthood had developed severe 
psychiatric pathology, which may indicate that EHMT1 haploinsufficiency is associated 
with neurodegeneration in addition to neurodevelopmental defect. 
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Introduction 
In the last decade, several microdeletion and duplication syndromes emerged from 
routine screening of subtelomere regions by Multiplex Ligation-dependent Probe 
Amplification (MLPA) and Fluorescent In situ Hybridization (FISH).[1-4] The 
chromosome 9q subtelomeric deletion represents one of the most common subtelomere 
deletions (6% of all).[3] In addition, the chromosome 9q subtelomere deletion syndrome 
(9qSTDS) is also one of the first clinically recognizable telomeric syndromes.[3,5-9] 
Affected individuals invariably have severe hypotonia with speech and gross motor 
delay. The facial features comprise micro- or brachycephaly, hypertelorism, synophrys or 
arched eyebrows, midface hypoplasia, a short nose with upturned nares, a protruding 
tongue with everted lower lip and down-turned corners of the mouth. Approximately half 
of affected individuals have congenital heart defects, primarily atrial or ventricular 
septum defects. A substantial part (10-20%) have epilepsy and/or behavioral and sleep 
disturbances. A variety of other major and minor eye, ear, genital and limb anomalies 
have been reported.[7-9] We demonstrated that the syndrome is caused by 
haploinsufficiency of Eu-chromatin Histon Methyl Transferase 1 (EHMT1) (Online 
Mendelian Inheritance in Man 607001), a gene involved in histone methylation.[10-15] 
Since this finding, we have implemented the testing for the 9q subtelomeric deletion 
syndrome in a DNA diagnostic setting. This analysis includes a screen for small deletions 
by a Multiplex MLPA approach and for intragenic EHMT1 mutations by direct 
sequencing of the gene in MLPA negative cases. To date it is not yet known if and to 
what extent the size of the deletions or type of EHMT1 mutations are related to particular 
features or severity of the 9qSTDS. Therefore we have carefully studied the clinical and 
molecular characteristics of a cohort of newly identified cases with the 9qSTDS.   
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Patients 
Patients included in this study were referred by clinical geneticists from the Department 
of Human Genetics of the Radboud University Nijmegen Medical Centre and through 
collaborating centers. All patients referred had the core phenotype of the 9qSTDS 
comprising mental retardation, hypotonia and facial characteristics. The cohort included 
16 patients with a known 9q deletion identified through routine subtelomere chromosome 
testing or whole genome array, who were referred for confirmation and/or further fine 
mapping of the deletion. In 14 cases the deletion was identified by routine subtelomeric 
MLPA (P070 MSRC Holland) or FISH (Vysis probe).[1-2] In the other two, a deletion 
was identified through whole genome array (Affymetrix 500k SNP array and custom 
oligonucleotide array EmArrayCyto6000_version2). The second cohort comprised 24 
patients with the typical manifestations of the syndrome but with normal routine 
MLPA/FISH results. The selection of patients for this cohort was carried out by two of us 
(TK and HGB) based on facial characteristics. 
 
Methods 
DNA was obtained from peripheral blood cells and extracted according to standardised 
procedures. MLPA and direct sequencing of the EHMT1 gene was carried out as 
described previously.[12] 
We used the structure of the pre-SET and SET-domains (PDB-file 2rfi) to study the effect 
of the missense mutations on the 3D-structure of the protein. The WHAT IF & Yasara 
Twinset (www.yasara.org) was used for analysis of the effects of the amino acid 
substitution towards the protein structure. A more extensive explanation of the 
methodologies and results is available online (http://www.cmbi.ru.nl/~hvensela/EHMT1). 
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Results 
Molecular analysis 
The size of 16 novel deletions is schematically shown in figure 1. Deletion fine mapping 
was performed in 16 patients in whom presence of a 9q deletion had already been 
suggested based on findings by routine telomere studies or genomewide array 
approaches. In seven patients the deletion was initially identified by FISH (patients 8, 9, 
10, 11, 12, 13 and 14) for another seven patients routine MLPA had been abnormal 
(patients 1, 2, 3, 4, 7, 15 and 16) and in two patients interstitial 9q deletions were found 
by microarray analysis: patient 5 by custom oligonucleotide array 
EmArrayCyto6000_version2 and patient 6 by Affymetrix 500k SNP array. The 
breakpoint and sizes of the deletions show a heterogeneous distribution. The most 
common deletion was found in six patients and had a size between 700 kb and 1.3Mb 
(figure 1). The largest one is 3.1Mb in size extending from CACNA1B to OLFM1 (patient 
2). The smallest one is 40 kb, comprising exon 11 to 25 of the EHMT1 gene exclusively 
(patient 6). 
Further deletion analysis followed by direct sequencing of EHMT1 was performed in 24 
patients with normal routine MLPA/FISH results. No additional deletions were identified 
by MLPA whereas in total, six novel intragenic mutations were found that are highly 
likely pathogenic (table 1). The mutations comprised two nonsense changes, c.778C>T 
and c.1717C>T (p.Arg260X, p.Gln573X) and one 4 bp deletion c.1440_1443del 
(p.Asp481fs), all three predicted to result in nonsense mediated mRNA decay (NMD). 
Two comprised de novo splice site mutations (c.2775-1G>A and c.2100-1G>C ). 
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Table 1: Clinical characteristics of patients with EHMT1 intragenic mutations and (interstitial) subtelomeric deletions 
 
 Patient Age* 
(y) 
Sex 
(M/F) 
Birth 
Weight 
(g, 
centile) 
Present 
Weight 
(kg, 
centile) 
Present 
Height 
(centile) 
Present 
OFC 
(centile) 
Heart 
defect 
Epilepsy Other MRI/CT 
cerebrum 
Interstitial            
 1 4 F 4500 
(>95th) 
 
50th 2-16th  innocent 
murmur 
-  Normal (MRI) 
 2 4 M 3200 
(25th) 
  33 cm 
at birth, 
(2nd) 
VSD 
aortic 
coarctation 
- micropenis, 
cryptorchidism 
VUR 
hearing loss  
inguinal, peri- 
umbilical and  
epigastric hernia 
Mildly dilated ventricles 
Reduction in white 
matter volume (MRI) 
 3 4 F 3800 
(75-
90th) 
>95th >>95th 50th Tetralogy of 
Fallot 
- mixed hearing 
loss umbilical 
hernia 
 
no data 
 4 52 F normal 50th 2nd 0.6th - absences  
tonic-clonic 
insults 
scoliosis small pons, slight 
central atrophy of both 
hemispheres (P.E.G 
examination) 
 5 8 M 3650 
(50-
75th) 
99.6th 98th 16th innocent 
murmur 
complex 
partial 
seizures 
 
inguinal and 
umbilical hernia 
increased CSF spaces 
over frontal lobes and 
Sylvian fissures 
compatible with atrophy 
(MRI) 
 6 7 M 50th 2nd 2nd 5th - - tracheo-
/bronchomalacia 
chronic renal 
insufficiency 
small brainstem (MRI) 
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 7 20 M 4350 
(.>90th) 
50th 3rd 50th - Abnormal 
EEG 
No epilepsy 
hearing loss 
small ears 
small hands 
supernumerary 
nipples 
cryptorchidism 
Normal (MRI) 
Telomeric            
 8 48 M 
 
 
4200 
(95th) 
25-50th 
 
 2nd - + asymmetric face Normal (CT) 
 9 33 F 
 
 
   2nd ASD +  no data 
   M 
 
2760 
(<5th ) 
 
2nd 16th 0.6th VSD/ASD - tracheomalacia no data 
 11 14 F 2300 
(<2 th ) 
98th 2nd 2nd VSD -  no data 
 12 20 M 3690 
(75th ) 
 
98th 98th 25th bicuspid aortic 
valve 
- VUR, GER 
Retained primary 
dentition 
Prominent Virchow-
Robin spaces (MRI) 
 13 4 M 3600 
(75th ) 
 
95th 95th 16th - - pes equinovarus Normal 
 14 21 M 4390 
(>95th ) 
 
84th 185 cm 
50th 
16th VSD tonic-clonic 
insults 
pyloric stenosis 
died age 21, cause 
unknown 
slight asymmetry 
anterior horns 
 
 15 12 M 3890 
(75-
90th) 
98th 16th 50th - - cryptorchidism arachnoidal cyst, 
supratentorial mildly 
enlarged CSF spaces (5 
yrs) 
 16          no data 
Intragenic 
EHMT1** 
           
c.2100-1G>C 17 3 F 4380 
(95th ) 
>> 99th >> 99th 50th - - - abnormal myelination 
(MRI) 
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c.2775-1G>A 18 13 F 4000 
(90th ) 
95th 50th 50th Patent FO 
(closed 
spontaneously) 
- constipation 
incontinent for 
urine/feces 
normal 
p.Arg260X 
(c.778C>T) 
19 7 M 3822 
(75-
90th) 
90th 90th 16th - first at age 7 
generalized 
with right 
posterior focal 
onset 
 mildly enlarged 
ventricles 
(MRI) 
p.Cys1042Tyr 
(c.3125G>A) 
20 7 F 4100 
(90th ) 
90th 75th 90th Pulm stenosis - glue ear requiring 
grommets 
hypermobile joints 
delayed secondary 
dentition at age 8 
normal myelination, 
normal ventricles, some 
prominence of Sylvian 
fissures with frontal 
lobe hypoplasia (MRI) 
p.Asp481fs 
(c.1440_1443del) 
21 2.6 F 2495 
(<5th) 
50th 84th <2 nd - -  normal 
p.Gln573X 
(c.1717CT) 
22 3 M 2690 
(<5th) 
  
<2nd - - GER 
cryptorchidism 
(prenatal NT) 
corpus callosum 
hypoplasia 
(MRI) 
     
  
     
 
VUR= vesico- ureteral reflux; GER= gastro-esophageal reflux; VSD= ventricular septum defect; FO= Foramen Ovale; ASD= atrial septum defect; PEG= pneumoencephalogram; 
CSF= cerebral spinal fluid 
 
*   Age of examination 
** GenBank Accession Number NM_024757.3 was used as a reference sequence. The A at the start codon was designated as nucleotide number 1. 
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These mutations have not been previously reported as pathogenic mutations, they are not 
present as non-pathogenic variants (http://www.ncbi.nlm.nih.gov/SNP/). In three cases 
the expected de novo occurrence was confirmed by analysing DNA from both parents, 
whereas forthree other cases with loss of function mutations, parents could not be 
analysed. Based on the prediction software for splice sites  
(http://www.fruitfly.org/seq_tools/splice.html, 
http://www.cbs.dtu.dk/services/NetGene2/, and  
http://www.genet.sickkids.on.ca/~ali/splicesitefinder.html), the c.2775-1G>A and c.2100-
1G>C changes  cause aberrant splicing. Finally, one de novo missense change 
c.3125G>A (p.Cys1042Tyr) was found. This mutation affects a highly conserved 
cysteine residue located in the pre-SET protein domain (fig 2).  
 
Protein modeling 
Cysteine 1042 is located in a cysteine cluster surrounding three zinc-ions. This 
cysteine/zinc-cluster is important for the local structure of this particular region of the 
pre-SET domain. The cysteines make strong interactions with the zinc-ions thereby 
placing the intervening loops in a correct position for dimer interactions. (Figure 3 and 
supplementary data http://www.cmbi.ru.nl/~hvensela/EHMT1/). Mutation of cysteine 
1042 into a tyrosine will abolish the strong cysteine/zinc interaction, causing a less stable 
domain. Moreover, the sidechain of tyrosine will not fit at position 1042. Introduction of 
this residue will completely disturb the structure of the zinc/cysteine-cluster and displace 
the residues in the loops that interact with the other monomer. The mutation will destroy 
the conformation of this domain that is needed for dimer-conta 
 
 Clinical data 
Individual descriptions of patients are summarized in tables 1 and 2.
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Table 2: Developmental, behavioural and psychiatric characteristics 
 
 Patient Psychiatric symptoms 
 behaviour features 
Development 
Interstitial    
 
1 
 
+ no data 
 
2 frustration and tantrums severely delayed only a few 
words uses signing and picture 
cards 
 
3 
 
temper  tantrums speaks some words 
 
4 disturbed sleep pattern 
aggressive outbursts 
active and passive periods 
 
regression  
sat at 18 months, walked at 4 yrs 
spoke a few words when young: 
papa, mama, car 
 
5 hyperactive, aggressive outbursts 
temper tantrums, disturbed sleep 
pattern 
autistic traits, hand flapping 
delayed 
sat at 11 months, walked at 
2.5yrs 
many single words some phrases, 
short sentences 
 
 
6 no data not walking at age 7 yrs 
3 words age 7 yrs 
 
7 psychoses 
passiveness  
temporarily regression at age 16 
yrs/dementia like  
 
Telomeric    
 8 aggressive behavior regression at age 28 yrs 
 
 9 mood disorder  
self-mutilation 
no data 
 10 - no data 
 11 - 
 
mild mental retardation 
 12 friendly 
since age 14 sudden mood disorder, 
withdrawal, catatonic(-like) period 
recovering at age 21 yrs  
sat at age 10 months, walked at 
age 22 months 
single words, some phrases since 
age 2 yrs 
    
 13 - 
 
sat at age 11 months, walked at 
age 20 months 
climbed stairs up and down age 4 
yrs 
few single words age 4 yrs 
 14 No data mild- moderate mental 
retardation 
 15 friendly boy, 
autistic behaviour 
sat at 10 months, walked at 18 
months 
speech delay, some writing and 
counting up to 20 
 16 no data no data 
Intragenic    
c.2100-1G>C 17 disturbed sleep pattern 
self-mutilation, hyperphagia 
walked at 17 months 
a few words at 5 yrs 
c.2775-1G>A 18 temper tantrums/tics  
rigid and ritualistic behavior 
severe mental retardation 
walked at age 30 months 
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apathic/depressive behavior with loss 
of all interests since age 13  
 
3-4 words 
 
p.Arg260X 19 poor eye contact, teeth grinding (all 
improving) 
walked at 2 yrs, jumping, 
running etc age 7 yrs 
5 words at age 3, >100 words 7 
yrs 
p.Cys1042Tyr 20 trusting and friendly personality severe mental retardation 
walked at 3yrs, can not run age 7 
yrs 
unable to ride bicycle 
some speech, in general ‘signs’  
p.Asp481fs 21 autism  spectrum walked at 22 months 
no speech 
p.Gln573X 22 autism  spectrum mild mental retardation 
    
 
 
Clinical information of affected patients was systematically obtained by a standard 
clinical data sheet. No additional clinical data were obtained for patient 16. All patients 
showed the core phenotype of the 9qSTDS comprising mental retardation, childhood 
hypotonia and recognizable facial features. Photographs showing the facial profile of 
several patients are shown in figures 4-7. Figure 4 shows five patients with an intragenic 
EHMT1 mutation. Figure 5 shows patients with obesity. When available and appropriate, 
series of photographs at different ages are depicted, showing the progression of the facial 
phenotype with age (figure 6 and 7). 
Birth weight in all patients was within or above normal range. In 4/15 deletion cases and 
3/6 EHMT1 intragenic mutation cases, birth weight was at or above 90th centile. 
Childhood obesity was present in the same 3 mutated cases and one additional case (19) 
and in 5 deletion cases, noteworthy overlapping only with one who had high birth weight 
(patient 15). Microcephaly was noted in 6/15 patients with a deletion and 2/6 cases with a 
mutation and was already present at birth. No secondary microcephaly was reported. The 
degree of mental retardation was moderate to severe. Most did not develop speech, 
though language development was usually at a higher level making communication by 
other means, such as sign language or pictograms possible. Variable cognitive function 
was noted. The best performance was in patient 11, with a deletion of minimal 970 kb, 
who can speak complete sentences (Total Intelligence Quotient, TIQ=52). 
Motor function was delayed, but all individuals were able to walk, usually independently 
between two and three years of age. A notable exception is patient 6 who has an out of 
frame intragenic EHMT1 deletion (exons 11-25) and who is not able to walk at present 
age (7 years). 
Variable congenital heart defects were observed in 7/15 deletion cases (ASD/VSD, 
Tetralogy of Fallot, aortic coarctation, bicuspid aortic valve and in patient 20 with the 
p.Cys1042Tyr EHMT1 mutation pulmonic stenosis). Genital defects were observed in 2/6 
males with a deletion (micropenis, cryptorchidism) and in 1/2 males with a mutation 
(cryptorchidism). In addition vesico-ureteral reflux (VUR) was noted in patients 2 and 12 
and chronic renal insufficiency was observed in patient 6 (intragenic EHMT1 deletion). 
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Other anomalies were tracheo-/ bronchomalacia with respiratory insufficiency and 
gastro-eosophageal reflux (GER). Epilepsy was present in 6/15 deletion cases comprising 
tonic-clonic seizures, absences and complex partial epilepsy and generalized with focal 
onset in patient 19 with the p.Arg260X EHMT1 mutation. Results of brain imaging by 
CT or MRI performed in 12 individuals were generally normal but individual patients 
had corpus callosum hypoplasia (patient 22), enlarged CSF spaces/cortical atrophy 
(patients 5,15,19,20), prominent Virchow-Robin spaces (patient 12), brain stem 
hypoplasia (patient 6) and abnormal myelinization (patient 17). 
Six patients reached adult age and were examined at respective 19, 20, 20, 33, 48 and 51 
years of age. One of these died at age 19, probably because of cardiac arrhythmia, but 
autopsy was not performed. No behavior characteristics were reported for this patient. In 
the other five adult patients an abrupt change in behavior and daily functioning was 
observed starting at adolescence but recovered to some extent in adulthood. All five had 
been under psychiatric care and used psychotropic medication. Abnormalities included 
apathy, aggressive periods, psychosis or (autistic) catatonia, bipolar mood disorder and 
regression in daily function and cognitive abilities.  
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Discussion 
In this study the clinical and molecular data of 22 novel identified patients with the 
9qSTDS are shown. Six of them had an intragenic EHMT1 mutation and the remaining 
16 had submicroscopic 9q deletions of variable size, including 7 interstitial deletions. The 
smallest deletion was 40 kb, taking out exons 11 to 25 of the EHMT1 gene exclusively. 
The seven interstitial deletions would have remained undetected by routine subtelomeric 
FISH analysis, since the probe that is commonly used for that purpose was not deleted. 
On the other hand, patient 15 showed abnormal FISH results, but unexpectedly, by 
validation with the standard MLPA probe (P070 in exon 9), normal results were found. It 
turned out that the proximal border of the deletion was disrupting the EHMT1 gene 
between exons 16 (not deleted) and 19 (deleted by MLPA). So neither routine 
subtelomeric testing with FISH nor with MLPA can exclude presence of 9q deletions in 
all cases. Therefore, we recommend that testing with the more extensive 9q MLPA kit or 
high resolution genomic profiling should be used to definitely discard such deletions. 
This study reports the smallest deletion reported so far, comprising only part of the 
EHMT1 gene (patient 6). Since it appeared that no other genes in the 9q region were 
involved, we considered this patient among the EHMT1 mutation cohort. This patient was 
known with tracheo-bronchomalacia and chronic renal insufficiency with unknown cause 
in addition to the core phenotype. The largest deletion in this study extended into the 
TRAF2 gene where the most proximal MLPA probe was located. By additional SNP 
array, it was shown that the deletion was 3.1Mb in size. This patient was born with 
several congenital abnormalities, encompassing micropenis, undescended testes, vesico 
ureteral reflux and aortic coarctation. It is possible that other genes in this larger deletion 
size are contributing to the severity of congenital defects seen in this patient, however all 
of these features have been observed also in patients with smaller deletions or EHMT1 
mutations.[6,9,12] Moreover, a previously reported case with a 2.2 Mb interstitial 9q 
deletion, which completely overlaps the proximal part of the 3.1Mb deletion described 
here, did not show any other major congenital abnormalities besides the mental 
retardation.[11] So this does not support a major contribution of genes proximal of 
TRAF2 to the severity of the phenotype. 
In 6 of 24 patients (25%) who were selected by us for exhibiting the 9qSTDS core 
phenotype, a pathogenic EHMT1 mutation was found. Five of six mutations disrupt the 
open reading frame of the EHMT1 gene and are predicted to create premature termination 
codons which may lead to nonsense mediated decay (NMD). Remarkably, one missense 
mutation was identified. Previously reported missense changes all turned out to be 
polymorphisms [12]. However, the p.Cys1042Tyr missense change in the current study is 
most likely causal for the phenotype because of the de novo occurrence. Another 
argument is that the mutation replaces a highly conserved cysteine residue in the pre-SET 
domain of the Eu-chromatin Histon Methyl Transferase 1 protein. As predicted by the 
pre-SET domain model, this mutation will strongly influence the local conformation the 
pre-SET domain. The phenotype observed in this patient (patient 20) is fully compatible 
with the 9qSTDS. She had severe psychomotor retardation, hypotonia and characteristic 
facial profile with midface hypoplasia, synophrys and eversion of lower lip. It thus 
appears that the p.Cys1042Tyr change has a dramatic effect on the protein function, and 
may reflect an EHMT1 null-allele just like mutations in the other patients. A dominant-
negative effect is not expected since complete absence of the protein is not believed to be 
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compatible with life.[15] Further functional studies could give additional proof for 
pathogenicity of this mutation. 
Another novel category among the mutations, are the two splice site changes. Both 
predicted to result in aberrant splicing and consequently, disruption of the open reading 
frame. There were no cells available to test this further. 
No significant differences were noted between previously reported patients with 9q 
subtelomeric deletions and patients with EHMT1 mutations (tables 1 and 3), except for 
high birthweight and childhood obesity. 
 
Table 3: Total percentage of features reported in patients with intragenic EHMT1 
aberrations reported in the current and in previous papers [10,12],  in relation to 
patients with deletions extending EHMT1 reported previously in literature. 
 
 Total 
 EHMT1 aberration 
N=10 
n (%) 
9q deletions 
N= >50 
% 
Features   
   
Mental retardation 10 (100%) 100% 
Hypotonia 10 (100%) 100% 
Birth weight > P90 5 (50%) 10% 
Childhood obesity 5 (50%) 20% 
Heart defect 3 (30%) 30% 
Genital defect (males) 2 (66%) 33% 
Renal disorder 
(incl. VUR) 
1 (10%) 14% 
Tracheomalacia 0 2% 
GER 0 2% 
Epilepsy 2 (20%) 30% 
Behavioral abnormality  8 (80%) 10% 
   
VUR= vesico-ureteral reflux; GER= gastro-esophageal reflux 
 
 
However, the frequency of features such as birth weight and behaviour/psychiatric 
aspects are not consistently reported in previous studies. In addition to the previously 
recognised childhood obesity that is present in a higher frequency in the 9qSTDS [6], it 
seems that birth weight tends to be higher as well. When considering also previously 
reported data, high birthweight has been reported in approximately 10% of patients with 
small 9q deletions and in 50% of patients with EHMT1 mutations (table 3). The 
prevalence of heart defects is 30% in both cohorts. One patient with the p.Cys1042Tyr 
had a pulmonic stenosis, one previously reported patient with the p.Arg1137X had a VSD 
and the originally reported patient with translocation breakpoint through EHMT1 had an 
ASD.[10,12] Another patient with a small deletion of 200kb, comprising only EHMT1 
gene and possibly ARRDC1 had a tetralogy of Fallot. 
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Seizures were present in 20% (mutation cohort) and in 30% (deletion cohort), presenting 
in infancy or adolescence with tonic-clonic insults (TCI), absences or grand mal. 
Epilepsy can present severely in the first year of life or later in childhood. Other features 
mentioned were recurrent ear nose and throat infections (8 patients), persistence of 
deciduous teeth (5 patients), pigmentation defect (1 patient), hearing loss (mixed or 
perceptive in 6 patients) and pes equinovarus (1 patient). A variable spectrum of 
behavioral abnormalities was observed in both patient categories. Frequently reported 
behavioral problems in younger children are temper tantrums, severe sleep disturbances 
and autistic features. However, sociable skills, friendliness and happiness were also 
mentioned. A sudden and dramatic change in behavior and performance was observed 
during adolescence in five of the six adult patients leading to psychiatric problems. These 
patients were diagnosed with psychosis, bipolar mood disorder and/or autistic-catatonia. 
Noteworthy, in two of them a transient or even permanent loss of functioning with loss of 
skills as toilet training and the ability to independent eating occurred. Disturbance of 
epigenetic gene regulation can result in regression of daily performance and cognitive 
abilities as demonstrated in Rett syndrome [MIM_312750]. Regression is one of the 
hallmarks of this condition that is caused by disturbance of chromatin modulation, 
through mutations in the Methyl-CpG- Binding Protein 1 (MeCP2) gene. [16] It has been 
shown that the MeCP2 protein thereby interacts with several interesting proteins, as the 
ATRX protein, a SWI2/SNF2 DNA helicase/ATPase [17], and histone methyl transferase 
Suv39H1. [16] To our knowledge, there is as yet no direct evidence as that any of these 
proteins directly interact with EHMT1. However, it has been demonstrated that Suv39H1 
is found in complexes with the paralog of EHMT1, the G9a protein [18], which in turn 
forms functional complexes with the EHMT1 protein. [15] This raises the question 
whether haploinsufficiency of EHMT1 similarly leads to regression in function and 
behavior pattern albeit at a later age. Further detailed neuropsychiatric studies are needed 
to get more insight into these features. Such information clearly will be of great 
importance to parents and caregivers of 9qSTDS patients. 
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Resources 
Online Mendelian Inheritance in Man (chromosome 9q subtelomere deletion syndrome #610253; EHMT1 
#607001): 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM&cmd=Limits 
 
Unique (Rare Chromosome Disorder Support Group in the United Kingdom): 
http://www.rarechromo.org/html/home.asp 
 
University of Nijmegen (clinical EHMT1 sequencing and MLPA screening): 
http://www.humangenetics.nl/en/diagnostics_en.php 
 
Emory University (clinical EHMT1 sequencing): 
http://www.genetics.emory.edu/testing/index.php 
 
USC Genome Browser (Assembly March 2006): 
http://genome.ucsc.edu 
 
3-D EHMT1 (pre-)SET domain structure and Cys1042Tyr  mutation: 
http://www.cmbi.ru.nl/~hvensela/EHMT1/  
 
Informed consent has been obtained for publication of all images present in this paper . 
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Legends to the figures 
 
Figure 1: 
Schematic drawing of the 9q subtelomeric region and the different deletion sizes 
identified. Indicated on the right the patients numbered corresponding to table 1, that 
were shown to have the respective deletion. Relative positions of routine FISH and P070 
MLPA probes are indicated.  
 
Figure 2: 
Domain structure of the EHMT1 protein and sequence identity of the pre-SET domain of 
EHMT1, the paralogous human gene EHMT2 (G9a), and the mouse and Drosophila 
orthologues. Note the highly conserved cysteine (arrow and underlined) that is mutated in 
patient 20.  
 
Figure 3: 
3A: Location of the Cys1042Tyr mutant. Cysteine 1042 is shown in red and is one of the 
cysteines in the cluster of cysteines (shown in yellow) that surround three zinc-ions 
(green). Interactions of the cysteines with Zinc are indicated as grey cilinders. The cluster 
is important for the correct position of the loops that interact with the other monomer 
(light blue surface).  
3B: Mutation of Cys1042Tyr. All cysteines in the cluster are coloured yellow, including 
cysteine 1042. This residue is mutated into a tyrosine (red), other colours are the same as 
the preceeding figure. The sidechain of tyrosine is shown to show the difference in size 
with the cysteine sidechain.  
Figure 4-7: 
Photographs of patients showing the characteristic facial profile comprising 
brachycephaly, hypertelorism, synophrys/arched eyebrows, midface hypoplasia, 
protruding tongue, eversion of lower lip and prognathism of chin. 
Informed consent has been obtained for publication of all images present in this paper . 
 
Figure 4: 
patients with EHMT1 mutations; patient 17 (AB), patient 18 (CD) 
patient 19 (EF), patient 21 (GH), patient 20 (IJ ) 
 
Figure 5: 
Patients 11 (ABC), 3 (DE) and 15 (FG) showing childhood obesity  
 
Figure 6 and 7:  
patients at different ages showing evolution with age. 
Patient 12 (row A), patient 18 (row B), patient 13 (row C), patient 4 (row D), patient 8 
(row E) and patient 7 (row F). Note asymmetric face in patient 8 
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